Shilpa Medicare Limited has announced the completion of its divestment of wholly owned subsidiary Koanna Healthcare Canada Inc. to an individual buyer for CAD 2000. The transaction was executed on January 14, 2026, through a Share Sale-Purchase Agreement with Mr. Steve N. Siliaty, a Quebec-based individual. Following this sale, Koanna Healthcare Canada is no longer a wholly owned subsidiary of Shilpa Medicare Limited.

Transaction Details

The sale involved the allotment of 2,84,21,020 equity shares of Koanna Healthcare Canada Inc. for a total consideration of CAD 2000. The Canadian entity ceased to be a wholly owned subsidiary of Shilpa Medicare Limited with effect from January 14, 2026.

Financial Impact

The subsidiary's contribution to Shilpa Medicare's overall business was minimal. Based on audited financial statements as of March 31, 2025, Koanna Healthcare Canada Inc. represented a negligible portion of the parent company's operations.

The company had already provided for this investment in the subsidiary, ensuring no impact on Shilpa Medicare's current financials. The divestment represents a strategic decision to exit a non-material international operation.

Regulatory Compliance

Shilpa Medicare has fulfilled all regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Key compliance aspects include:

• The subsidiary was not classified as a material subsidiary under Regulation 16
• The transaction does not constitute a related party transaction
• The sale is outside any scheme of arrangement
• Full disclosure has been provided to stock exchanges

The transaction documentation and related disclosures are available on the company's website. This divestment allows Shilpa Medicare to focus resources on its core pharmaceutical operations while maintaining compliance with all applicable regulations.

Shilpa Medicare has received an ex-parte ad-interim injunction order from the Delhi High Court regarding pharmaceutical products containing Ruxolitinib compound. The injunction, dated December 29, 2025, restrains the company and its subsidiaries from manufacturing, stockpiling, exporting, or supplying products containing this compound due to alleged patent infringement.

Court Order Details

The Delhi High Court has issued a restraining order against Shilpa Medicare Limited, along with its material subsidiary Shilpa Pharma Lifesciences Ltd and wholly owned subsidiary FTF Pharma Pvt Ltd. The injunction specifically prohibits these entities from manufacturing, stockpiling, importing, selling, offering for sale or supply, and exporting Ruxolitinib in any form beyond what is permissible under Section 107A of the Patent Act, 1970.

Inspection and Compliance

Following the court order, a Local Commissioner and team visited the company's office premises to conduct inspections. During this visit, officials took relevant copies of ledgers, stock registers, and other documentation. The company reported full cooperation with officials during the proceedings and responded to all clarifications and details sought by the inspection team.

Company's Position and Impact

Shilpa Medicare has clarified that the Ruxolitinib product in question was utilized exclusively for research purposes. The company emphasized that there is no financial impact expected from this development, and business operations continue as usual without disruption from the court proceedings.

Legal Response and Next Steps

The company has duly acknowledged receipt of the ex-parte ad-interim injunction order and has taken necessary steps to comply with all directions contained therein. Shilpa Medicare is currently evaluating its legal options, including the possibility of filing appropriate responses or appeals, as advised by legal counsel. The company disclosed this information in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.